RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
ONCOTARGET
Collezione AO Cuneo

Items : 9

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213. eCollection 2018 Oct 2.

2018
ASL Città di Torino
AO Cuneo

Clivio L; Torri On Behalf Of The Eva Study Group V; Frassoldati A; Scavelli C; Palumbo R; Ferzi A; Schirone A; Cursano MC; Fabi A; Gebbia V; Benedetto C; Atzori F; Turletti A; Blasi L; Piezzo M; Artale S; Mentuccia L; La Verde N; Bianchi G; Musolino A; Vici P; Maur M; Pistelli M; Garrone O; Generali D; Zambelli A; Febbraro A; Arcangeli V; Diodati L; et alii...

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431. eCollection 2018 Nov 30.

2018
ASL Città di Torino
AO Cuneo

Torri V; Frassoldati A; Clivio L; Scavelli C; Ferzi A; Palumbo R; Gebbia V; Schirone A; Fabi A; Benedetto C; Cursano MC; Turletti A; Atzori F; Artale S; Blasi L; Piezzo M; Bianchi G; Maur M; La Verde N; Mentuccia L; Vici P; Musolino A; Pistelli M; Garrone O; Generali D; Zambelli A; Febbraro A; Arcangeli V; Diodati L; et alii...

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. in Oncotarget / Oncotarget. 2018 May 4;9(34):23443-23450. doi: 10.18632/oncotarget.25215. eCollection 2018 May 4.

2018
AO Cuneo
AOU Città della Salute di Torino

Zinzani PL; Trentin L; Morello L; Argnani L; Desabbata G; Scortechini I; Castellino C; Mastrullo L; Marasca R; Santambrogio E; Vanazzi A; D'Alò F; Rigolin GM; Ilariucci F; Molica S; Cascavilla N; Tosi P; Di Renzo N; Baldini L; Zilioli VR; Paolini R; Visco C; Merli M; Pisani F; Spina F; Ferrero S; Volpetti S; Spina M; Gotti M; et alii...

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. in Oncotarget / Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.

2018
AOU Città della Salute di Torino
AO Cuneo

Boni L; Zagonel V; Di Donato S; Ricci V; Allegrini G; Buonadonna A; Racca P; Zaniboni A; Tomasello G; Ronzoni M; Moretto R; Cortesi E; Citi V; Marmorino F; Borelli B; Loupakis F; Bergamo F; Lonardi S; Antoniotti C; Del Re M; Cremolini C; Falcone A; Danesi R;

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Aug 7;9(61):31877-31887. doi: 10.18632/oncotarget.25874. eCollection 2018 Aug 7.

2018
ASL Città di Torino
AO Cuneo

Torri On Behalf Of The Eva Study Group V; Clivio L; Scavelli C; Frassoldati A; Ferzi A; Palumbo R; Gebbia V; Schirone A; Fabi A; Cursano MC; Turletti A; Benedetto C; Atzori F; Piezzo M; Artale S; Blasi L; La Verde N; Bianchi G; Maur M; Mentuccia L; Vici P; Musolino A; Garrone O; Pistelli M; Zambelli A; Febbraro A; Generali D; Diodati L; Arcangeli V; et alii...

Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. in Oncotarget / Oncotarget. 2017 Aug 10;8(45):79884-79896. doi: 10.18632/oncotarget.20168. eCollection 2017 Oct 3.

2017
AO Cuneo

Gamucci T; Quadrini S; Palazzo S; Di Cicilia R; Cavanna L; Rubino D; Pinto C; Maiorana L; Iacono C; Imperatori M; Tonini G; Bergo E; Zagonel V; Marchetti L; Pavese I; Chiurazzi B; Carteni G; Magarotto R; Gori S; Plastino F; Barone C; Saracino V; Lorusso V; Farcomeni A; Lucia S; Muscaritoli M; Minardi S; Merlano M; Colucci G; et alii...

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. in Oncotarget / Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.

2017
AOU Città della Salute di Torino
AO Cuneo

Cuneo A; Cavo M; Vianelli N; Breccia M; Bacchi Reggiani ML; Merli F; Fanin R; Lemoli RM; Vitolo U; Di Raimondo F; Aversa F; Catani L; Sabattini E; Spinsanti M; De Matteis G; Anaclerico B; Cerqui E; de Marchi F; Scaffidi L; Di Veroli A; Latagliata R; Bosi C; Crugnola M; Ibatici A; Cavazzini F; Tieghi A; Bergamaschi M; Polverelli N; D'Adda M; et alii...

Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies. in Oncotarget / Oncotarget. 2017 Feb 7;8(6):9174-9188. doi: 10.18632/oncotarget.13942.

2017
AO Cuneo

Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G;

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. in Oncotarget / Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22.

2017
AO Cuneo

Ciliberto G; Di Cocco B; Marolla P; Sanguineti G; Garrone O; Della Giulia M; Laudadio L; Greco F; Barni S; Lorusso V; Cannita K; Russo A; Adamo V; Giotta F; Tomao S; Ficorella C; Alberti AM; Landucci E; Rossi E; Barba M; Maugeri-Saccà M; Sini V; Mauri M; D'Onofrio L; Scinto AF; Zampa G; Bertolini I; Botticelli A; Piacentini F; et alii...